Alnylam Reports Phase I Clinical Safety Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of RSV Infection; Results Reported at the 2006 Pediatric Academic Societies' Annual Meeting.

Publication: Business Wire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2006 Business Wire

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the company's lead product candidate, ALN-RSV01, was found to be safe and well tolerated when administered intranasally in two Phase I clinical studies. ALN-RSV01 is being evaluated for the treatment of respiratory syncytial virus (RSV) infection and is the first RNAi therapeutic in human clinical development for an infectious disease. E[acute accent]"These Phase I study results are an important step forward for Alnylam and for the entire field of RNAi therapeutics. Data from these trials provide us with a significant clinical experience for ALN-RSV01 with 101 subjects enrolled in the two trials combined," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. "Treatment of RSV infection, the leading cause of pediatric hospitalization in the U.S. today and a prevalent infection in certain adult populations, represents a major unmet medical need in a large number of patients. We believe that ALN-RSV01 is a promising treatment option for these patients and, as an unpartnered clinical program, an important component of Alnylam's balanced pipeline of wholly owned and partnered RNAi therapeutics." E[acute accent]"As a clinician committed to the advancement of new therapies for the treatment of pediatric infectious diseases, I am very encouraged by the results of these first human studies with ALN-RSV01," said John...

Read the full article for free courtesy of your local library.